Anthem Biosciences Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹46,104 Cr
- Book Value
- ₹54.2
- Stock P/E
- 77.7
- Dividend Yield
- 0.24%
- ROE
- 22.3%
- ROCE
- 30.4%
- PEG Ratio
- 4.45
- EV/EBITDA
- 48.3
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Anthem Biosciences share price today
Anthem Biosciences (NSE: ANTHEM) is the rare Indian CRDMO built on fermentation plus synthesis — it can make molecules by chemistry or by biology, a dual capability few contract researchers anywhere offer. Global innovators use it from discovery through commercial manufacturing, and the P&L shows what differentiated science earns: a 39.6% operating margin — the highest in Indian CRDMO — with 30% ROCE and near-zero debt.
The complication is entirely in the price. Listed in July 2025, Anthem trades at 77.7× earnings with a PEG of 4.45 on a one-year public track record. Our universe keeps it on watch: the science is proven, the public-market history isn’t, and the multiple assumes it will be.
What the dual platform buys
CRDMO revenue compounds through wallet-share: a molecule captured in discovery becomes development revenue, then commercial-supply revenue that persists for the drug’s life. Anthem’s fermentation capability adds biologics-adjacent work (enzymes, peptides, fermentation-derived APIs) that pure chemistry shops must decline — widening the funnel at its most defensible point. China-plus-one continues to redirect innovator budgets toward exactly this profile.
Watch-items: client concentration typical of young CRDMOs, capacity-expansion execution, margin durability as scale projects mix in, and the post-listing lock-in/track-record seasoning every 2025 IPO must earn through.
The numbers
From our research universe snapshot (5 Aug 2026):
| Metric | Value |
|---|---|
| Market cap | ₹46,104 Cr |
| P/E (TTM) | 77.7 |
| EV/EBITDA | 48.3 |
| Operating margin | 39.6% |
| ROE / ROCE | 22.3% / 30.4% |
| Debt to equity | 0.02 |
| Sales CAGR (5y) | 14.0% |
| Profit CAGR (5y) | 17.5% |
| Promoter holding | 71.4% |
| EPS (TTM) | ₹10.54 |
Anthem Biosciences share price target 2026 to 2030
EPS base ₹10.54 (TTM). Bear: growth stays mid-teens and the multiple halves — 10% growth at 35×. Base: China-plus-one accelerates bookings — 18% growth at 55×. Bull: commercial molecules scale and margins hold — 25% growth at 75×.
| Year | Bear (35×, +10%) | Base (55×, +18%) | Bull (75×, +25%) |
|---|---|---|---|
| 2026 | ₹406 | ₹684 | ₹988 |
| 2027 | ₹446 | ₹807 | ₹1,235 |
| 2028 | ₹491 | ₹952 | ₹1,545 |
| 2029 | ₹540 | ₹1,125 | ₹1,930 |
| 2030 | ₹594 | ₹1,325 | ₹2,410 |
From ₹819, the base case is ≈ +62% over four and a half years — but note what it requires: growth accelerating well past the historical 14–17% while the multiple only drifts down to 55×. The bear case is −27% on nothing worse than “stays a good company at a normal price.” That gap is why the entry range below is strict.
Reasons to own Anthem Biosciences (at the right price)
- 40% operating margins — evidence of genuine scientific differentiation, not capacity arbitrage.
- Fermentation + synthesis dual platform that widens the innovation funnel.
- CRDMO wallet-share economics: discovery wins compound into commercial annuities.
- China-plus-one is a decade-scale reallocation of innovator spending.
- Near-zero debt and 30% ROCE fund expansion internally.
The risks: a 78× multiple prices years of acceleration that hasn’t happened yet, one lost anchor client dents a young revenue base, and 2025-vintage listings have lock-up expiries and unproven public governance.
Should you buy at the current price?
The live buy range below is for members — where a great platform stops needing a perfect future.
FAQ
What is the Anthem Biosciences share price target for 2030? Base case ≈ ₹1,325 (55× on 18% compounded growth), bear ≈ ₹594, bull ≈ ₹2,410. Arithmetic above.
What makes Anthem different from other Indian CRDMOs? The fermentation platform. Most Indian contract researchers are synthesis-only; Anthem can take on biology-derived molecules too, which shows up directly in its sector-leading margins.
Is the 78× multiple ever justified? Only by acceleration. At the historical mid-teens growth, arithmetic says the multiple must compress; the bull case requires bookings growth the short public history can’t yet evidence either way.
When are Anthem’s next results? Track the exact date on our results calendar.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.